http://www.medboundtimes.com/, https://biography.medboundtimes.com/

MedBoundtimes, Chicago, IL (2026)

10/05/2026

"For millions of people around the world, managing a long-term health condition means remembering to take medicines every day, often for years. But advances in long-acting medicines mean that some treatments now need to be taken only once a month, every few months or even twice a year.

Long-acting medicines are designed to release a drug gradually into the bloodstream. For some conditions, this could make treatment easier to manage and reduce the risk of missed doses.

Medicines prescribed for long-term conditions work best when taken as directed. But taking medicine regularly can be difficult, particularly when people need several medicines or multiple doses each day. Some people forget. Others may stop taking treatment when they start to feel better or because of side-effects.

Missed doses can have consequences. With antibiotics, for example, not taking treatment as prescribed can contribute to treatment failure and antimicrobial resistance. Antimicrobial resistance happens when bacteria and other microbes change in ways that make medicines less effective against them. It’s estimated that bacterial antimicrobial resistance was associated with 4.95 million deaths worldwide in 2019.

Antimicrobial resistance is also making the development and use of antibiotics increasingly difficult and expensive. High development costs and limited financial incentives mean that few new antibiotics are being brought to market, and many of those currently in use are based on drugs developed decades ago.

Missed doses can also lead to a condition getting worse and increase pressure on healthcare services. In the UK alone, unused prescriptions are estimated to cost the NHS more than £300 million each year. Unused medicines and their packaging also create waste. Blister packs for tablets, for example, are made from several materials and cannot usually be recycled through normal household collections..."

Link in Comment Section to read full story

[ long-acting medicines replace daily tablets]

10/05/2026

"The victim, identified as Darya Shipilova, was a 28-year-old researcher working at Irkutsk Anti-plague Institute in Siberia.

According to news outlet Lyudi Baikala, Ms Shipilova told medical staff she had accidentally broken the test tube holding live bacteria. She then became unwell while on a field expedition with colleagues in Buryatia, located near Russia's eastern border with Mongolia.

She was admitted in Shelekhov Hospital where doctors reported that she was experiencing severe pneumonia-like symptoms and was eventually put on a ventilator. Her condition continued deteriorating, and she died two days later.

In an account with The Moscow Times, Mikhail Favorov, a senior Russian epidemiologist, dismissed the broken test tube explanation. He mentioned that researchers working in institutions like the Anti-plague Institute in Irkutsk always follow safety precautions and wear safety gear. He further added, “If you break a test tube, the likelihood of infection is actually very low. In short, it doesn't matter to the general public – they'll believe the ‘broken test tube’ story.”

Following the incident, there was no immediate statement from Russia's health ministry. Alexei Tsydenov, who is the governor of Russia's Buryatia region, said in a social media post that a woman in the neighbouring Irkutsk region had 'died of plague'.

The chief state sanitary doctor of Russia, Anna Popova, rushed 2,600 miles from Moscow to Siberia to take personal charge of the outbreak. According to reports, a mask decree has also been implemented in Irkutsk.

Igor Kobzev, Governor of Irkutsk, said, “We held an extraordinary meeting of the regional sanitary and anti-epidemic commission with the participation of Russia's Chief State Sanitary Doctor Anna Popova. The reason was information that had emerged about a suspected case of a particularly dangerous infectious disease in a resident of the region.”

Link in Comment Section to read full story

[ plague outbreak in Russia, Russia plague cases and health alert]

10/03/2026

"A donkey has secured a nursing certificate from the Madhya Pradesh government. According to the reports, the donkey’s photo was uploaded on the official portal, his personal details were meticulously filled in the online form. A few blank documents were uploaded as proof of education. After the payment of the application fees, the regulatory authority issued a provisional certificate to the donkey.

The flimsy application was filled by Ravi Parmar. who is the MP Vice President of National Students Union of India, the student wing of Congress.

In the application form, Parmar filled in the father’s name as ‘Donkey Father’, Religion as ‘Other’, caste as ‘Animal’ and an address along the lines of ‘wherever there is space’. He also uploaded an AI generated image of a donkey on the application form.

After paying an online fee of Rs. 2,050, a certificate was issued to the donkey on September 25. The certificate stated that the donkey completed BSc Nursing training from Bhopal Nursing College between July 16, 2021, and August 13, 2025. The certificate also stated that the donkey was a “Registered Nurse and Registered Midwife” and that the registration was valid till 2031.

The MPNRC also issued the registration number ‘AI – 74561, DII – 73911’ to the fake donkey applicant. The certificate also stated that it was valid for five years, from 25/09/2026 to 24/09/2031.

NSUI stated that such irresponsible functioning of the state government-run MPNRC needs to be audited immediately. “It is not even by mistake or any typing error that the MPNRC issued the registration certificate to a donkey, as all the details in the online application form were actually filled as donkey and donkey father only,” Viraj Yadav, the NSUI national spokesperson, told The Statesman on Tuesday..."

Link in Comment Section to read full story

[ MPNRC donkey nursing certificate, donkey registered as nursing student]

10/03/2026

"How do we know when an animal virus might pose a risk to humans? Canada confirmed a human case of H5N1 avian influenza (often called “bird flu”) in 2024, the first ever known to have been acquired in Canada. The patient, a thirteen-year-old British Columbian, suffered severe symptoms including respiratory failure but recovered with intensive care in hospital.

Uncovering insights into how pathogens can switch from animals to humans — as in this human case of bird flu — can help researchers and public health agencies prepare for future outbreaks. In a recent study, our lab examined viral mutations in this case and uncovered an unexpected result: the effects of these mutations were inconsistent with the usual warning signs we expect to see in a virus adapted to infect humans.

Public health agencies and collaborating groups use complementary approaches to monitor infectious disease outbreaks and risk. Human outbreak data comes from many places, including care settings and associated surveillance labs, volunteers reporting disease status, and wastewater monitoring. Current routine virological tests in public health labs include sequencing viral genes, testing for antiviral resistance and assessing immunity against strains of interest.

From wildlife and agricultural monitoring, Canadian agencies have tracked the arrival of the currently dominant H5N1 lineage of avian influenza, of which the B.C. case is a member. In this case of a human H5N1 patient in B.C., sequencing efforts found three mutations of interest. One is already a well-studied sign of adaptation from birds to mammals.

Immunity and Society is a new series from The Conversation Canada that presents new vaccine discoveries and immune-based innovations that are changing how we understand and protect human health..."

Link in Comment Section to read full story

[ bird virus infects humans, avian virus human infection]

10/01/2026

"In June 2026, Health Minister Sophie Hermans informed the public that a child under 12 years had died from euthanasia in 2025 due to severe illness, marking the first case of euthanasia of a child under 12 years of age.

However, according to new reports by the committee that reviews all late-term abortions and medically assisted deaths of children, the child was almost 24 months old.

The child was born prematurely at 26 weeks. The premature birth led to “extensive brain damage” and multiple infections, causing sepsis when the child was just 4 months old.

At 8 months old, the child was additionally diagnosed with a rather critical form of epilepsy known as infantile spasms syndrome (West syndrome) and cerebral palsy. The seizures caused the child to develop sleeping disorder, respiratory problems, coughing fits and a swallowing disorder.

After discussing the prognosis and discussing treatment options with the physician, the parents decided to terminate the child’s life. According to the report, the committee found that “the physician had acted with due care” given the circumstances.

Voluntary euthanasia or active euthanasia, when a medical professional ends a person’s life at their request, was legalized in the Netherlands in April 2002, making it the first country in the world to offer the option.

According to the Netherlands law, minors can request euthanasia from the age of 12 as long as they’re capable of assessing and understanding what’s best for them.

Children ages 12 to 15 require parental or guardian consent.

For minors who are 16 or 17, parents or guardians must be consulted in the decision-making process, but their consent is not required.

In 2024, the law was extended to allow children under the age of 12 to be euthanized if the child is “terminally ill and is suffering unbearably with no prospect of improvement.”

Link in Comment Section to read full story

[ Netherlands euthanasia for 1-year-old child, child euthanasia law Netherlands]

10/01/2026

“It’s so exciting to me to watch someone learn a new word or have that spark of understanding,” she said.

Zulick knew she could earn enough money as a substitute teacher to make going back to school financially viable — except for the cost of health insurance. She didn’t want to risk being unable to see her doctor for her allergies, or for preventative care.

The health insurance offered through Montana State University was too expensive, Zulick said, almost as much as her tuition. But then she found a solution that allowed her to make the leap: Medicaid. She wouldn’t have to pay any monthly premiums.

It worked well for a few months, as Zulick taught by day and took online classes at night.

But in June, the state sent a letter that she said left her “completely confused.” She knew Montana was rolling out a system for work requirements over the summer, but she thought she wouldn’t have to prove she met the requirements until next year, when her Medicaid enrollment came up for renewal.

Yet the letter from the Montana Department of Public Health and Human Services outlining the new requirements gave conflicting information on when Zulick would have to prove she was meeting them. First it said at her next renewal, which would be sometime next spring. Lower down it told her she would have to submit paperwork to prove compliance much earlier — “within 30 days” of the date on the letter, June 26. She wondered: Was it a boilerplate mass-mailing letter she could ignore, or was her insurance on the line?

Most states must implement the new work requirements by Jan. 1, but three states — Montana, Nebraska, and Arkansas — have already gotten started. Medicaid advocates worry that the expedited timeline in those states will lead to thousands of people losing coverage because they’re confused about the new rules, even if they are eligible for the program — and that Montana may offer a troubling preview of what will happen nationwide next year..."

Link in Comment Section to read full story

[ Medicaid work rules early rollout, US Medicaid eligibility changes]

09/30/2026

"The clinical study titled ‘Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicenter randomized double-blind placebo-controlled trial’ was published on 20 August, 2026 in Frontiers in Medicine.

The clinical trial was randomized, double-blind, placebo-controlled and multi centered. Researchers from 9 institutions conducted the study. Around 45 multidisciplinary experts monitored the trial across various sites, bringing together expertise across ayurveda, clinical medicine, rheumatology, complementary and integrative health and related disciplines.

The Ayush Ministry funded study was conducted across seven study sites in India and included clinical, laboratory and immunological assessments. The trial was registered with the Clinical Trials Registry–India.

1,200 healthy adults aged between 18 to 70 years were recruited for the study. The recruitment criteria included that participants should have received a first, second or booster dose of the COVISHIELD vaccine.

Participants were randomly assigned to receive either 500 milligrams of a standardized aqueous Ashwagandha root extract daily, equivalent to four grams of raw root powder, or a matching placebo. The intervention continued for 24 weeks, with participants followed up until week 28.

Out of the 1,200 recruited participants, 1,032 completed the study. The participants were closely monitored for 24 weeks by ‘comprehensive clinical and laboratory assessment’.

Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush said that “High-quality clinical research strengthens the scientific evidence-base of Ayurveda and contributes to a deeper understanding of its potential within contemporary healthcare. The growing body of evidence from rigorous clinical studies is also supporting the responsible global utilization of Ayurveda and its interventions across health and wellness settings.”

Link in Comment Section to read full story

[ Ayush Ministry on Ashwagandha]

09/30/2026

"The United States has exempted certain specialty pharmaceutical products and their associated ingredients imported from India from a new 100% tariff, giving Indian drugmakers relief as Washington moves to raise duties on some pharmaceutical imports.

The 0% tariff rate does not apply to every drug on the shelf, it is targeted at specialized medicines. The exemption covers India with 19 other countries. The US Commerce Department published the list ahead of the new tariff taking effect on September 29. The zero duty rate applies to a range of specialty medicines and their ingredients. These include drugs used to treat rare diseases, fertility medicines, cell and gene therapies, antibody drugs and certain plasma derived nuclear medicines. Some medicines used for animal health are also covered.

The exemption is particularly relevant for medicines where higher import duty could affect supplies to the US.

India was included alongside key global partners such as The EU (European Union), the UK, Japan, South Korea, and Taiwan because these countries already have trade and security deals with the US or are in talks to make such agreements.

For Indian pharma exporters, the decision offers greater clarity and protects a key part of the country’s export sector. Everyday medicines, which make up most of India’s drug exports to the US, will not be affected by the tariffs. Supplies of Indian generic medicines are expected to continue as usual.

The zero duty rate could also encourage Indian biopharma companies to invest in research and the production of advanced medicines..."

Link in Comment Section to read full story

[ US waives tariff on Indian specialty drugs, Indian specialty medicines tariff exemption]

09/29/2026

"Researchers from NUS have developed a next-generation electronic skin that can both sense and directly visualise pressure in real time, addressing key limitations of current wearable sensing technologies.

Electronic skin systems are increasingly used in healthcare, robotics and wearables, but most rely on arrays of sensors connected to external electronics for signal processing and display. These designs often face limitations such as low spatial resolution, wiring complexity and inefficient signal interpretation, making intuitive real-time feedback difficult.

To address these challenges, a team led by Professor Lim Chwee Teck from the NUS Department of Biomedical Engineering and the Institute for Health Innovation & Technology (iHealthtech) developed a soft, ultrathin device called the “eLuminator”. The findings were published in Nature Communications on May 2026.

Unlike traditional electronic skins that rely on discrete sensing pixels and typically achieving less than 100 dpi (where dpi indicates how finely pressure details can be resolved within a given area), the eLuminator uses a continuous, pixel-free design. With a spatial resolution of approximately 30 µm (847 dpi), it can detect much finer pressure details, enabling high-precision tactile sensing for advanced applications.

At the core of the technology is a mechano-electroluminescent response, where applied pressure directly changes the device’s light emission. When pressure is applied, the device generates visible light patterns that map both the magnitude and shape of contact. This enables immediate and intuitive visualisation without the need for separate processing or display systems.

The high-resolution luminescent response allows fine surface features such as the ridges and valleys of fingerprints to be clearly captured in real time, demonstrating its capability for detailed tactile imaging and potential use in biometric applications..."

Link in Comment Section to read full story

[ Electronic skin technology, artificial skin senses touch]

09/29/2026

"Vantara —a privately owned wildlife rehabilitation and conservation center in Motikhavdi, Jamnagar district, Gujarat – is again in the headlines after twenty seven NGOs wrote an open letter asking Vantara to stop importing exotic wildlife on September 26th, 2026 - after the facility announced a self-imposed moratorium on all animal imports.

Founded by the youngest son of billionaire Mukesh Ambani, Anant Ambani, the organization is funded through the Reliance Industries’s foundation. Vantara houses around 150,000 animals representing over 2,000 species across an area spanning approximately 3,500 acres of land inside the Reliance Jamnagar Refinery Complex.

On August 19, Vantara released a press statement announcing a series of “voluntary commitments” including a 12 month moratorium — running through June 2027 — on all animal imports, backdated to June 5, 2026.

The statement also noted that the organization had withdrawn all pending import applications and would not submit any new ones.

The press release also included a letter addressed to India’s Convention on International Trade in Endangered Species of Wildlife Fauna and Flora (CITES) Management Authority, which oversees international trade of endangered plants and animals listed under CITES, a global wildlife trade treaty.

The facility’s acquisitions include some of the world’s most endangered and classic species, such as:

Spix’s macaw (Cyanopsitta spixii) — extinct in the wild.

The critically endangered Tapanuli orangutan (Pongo tapanuliensis)

Galapagos iguanas, which have allegedly never been legally exported from the archipelago.

The press release came after investigations accusing the facility of illegally acquiring animals and allegedly smuggling indigenous species from countries in Africa, Asia, and Latin America..."

Link in Comment Section to read full story

[ Vantara wildlife imports, 27 global NGOs demand]

MedBoundtimes

10/05/2026

10/05/2026

10/03/2026

10/03/2026

10/01/2026

10/01/2026

09/30/2026

09/30/2026

09/29/2026

09/29/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Listing takedown request